This is the authors' abstract. We don't add key points for this paper.
We found that risk-based PAC screening in patients with NOD is likely to be cost-effective in the United States if even a modest fraction (>25%) of screen-detected patients with PAC are resectable. Future studies should reassess the value of this intervention once clinical trial data become available.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: